The U.S. drug regulator on June 29 declined to approve MediWound Ltd.’s topical burn treatment NexoBrid, sending the company’s shares tumbling in trading.

Mallinckrodt plc announced positive top-line results from the global biopharmaceutical company’s pivotal Phase 3 clinical trial of the investigational StrataGraft regenerative tissue.

To prepare for radiological and nuclear emergencies, the U.S. Department of Health and Human Services (HSS) announced it will work with Argentum Medical LLC to repurpose the company’s commercial Silverlon technology for radiation injuries of the skin.

Israel-based MediWound has signed a five-year, $112 million contract with the U.S. authority that handles public health medical emergencies to further develop and buy the company’s drug treatment for severe burns. Investment group Clal Biotechnology, which has a 45 percent stake in MediWound, said in a statement that the deal with the Biomedical Advanced Research […]